Printer Friendly

SCHERER ANNOUNCES PLANS TO FILE SECONDARY OFFERING

 SCHERER ANNOUNCES PLANS TO FILE SECONDARY OFFERING
 TROY, Mich., Sept. 10 /PRNewswire/ -- R.P. Scherer announced today


that it has been asked to file a registration statement with the Securities and Exchange Commission relating to a proposed secondary public offering of approximately 3.5 million shares of the company's common stock.
 The company said that the secondary shares being sold are held by affiliates of Shearson Lehman Brothers Holdings Inc., which own approximately 2.25 million shares and will sell all of these shares. In addition, the Lehman Brothers Merchant Banking Partnerships, which are comprised of an international group of institutional and individual investors and which own approximately 8.28 million shares of Scherer stock, will sell approximately 1.25 million shares in the offering and will provide the underwriters an over-allotment option to purchase up to an additional 500,000 shares. The Lehman Brothers Merchant Banking Partnerships will continue to own approximately 6.53 million shares or 28 percent of the company after the offering. Neither the company nor any of the officers or directors of the company will sell any shares in the offering. The offering will be made only by means of a prospectus.
 The company will file the registration statement in the near future.
 Shearson and its Merchant Banking Partnerships, together with the current senior management of the company, funded the acquisition of R.P. Scherer in 1989.
 In commenting on the proposed filing, a Scherer spokesman said that "this offering will broaden the shareholder base for Scherer's stock at a time when the company is attracting growing interest from the investment community. We look forward to our continued partnership with the Lehman Merchant Banking Partnerships."
 R.P. Scherer Corporation (NYSE: SHR), a leading international developer and manufacturer of drug delivery systems, is the world's largest producer of soft gelatin capsules ("softgels"). The company is currently developing and commercializing advanced drug delivery systems, including SCHERERSOL(R), ZYDIS(R) and PULSINCAP(TM) technologies. The company's proprietary drug delivery systems improve the efficacy of drugs by regulating the dosage, rate of absorption and place of release. The company operates a global network of 15 facilities in 11 countries.
 -0- 9/10/92
 /CONTACT: Aleksandar Erdeljan of R.P. Scherer, 313-649-0900/
 (SHR) CO: R.P. Scherer Corporation ST: Michigan IN: MTC SU: OFR


ML -- DE005 -- 7865 09/10/92 09:17 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Sep 10, 1992
Words:393
Previous Article:CIRCON INTRODUCES DIGITAL MEDICAL VIDEO SYSTEM
Next Article:DYNA GROUP PHASING OUT SUBSIDIARY
Topics:


Related Articles
SCHERER ANNOUNCES AN INITIAL PUBLIC OFFERING OF ITS SUBSIDIARY, PACO PHARMACEUTICAL SERVICES, INC.
SCHERER AND PACO ANNOUNCE SUCCESSFUL COMPLETION OF INITIAL OFFERING OF PACO'S COMMON STOCK
SCHERER ANNOUNCES A SECONDARY OFFERING AND FILES A REGISTRATION STATEMENT
R.P. SCHERER ANNOUNCES PUBLIC OFFERING OF ITS COMMON STOCK
SCHERER HEALTHCARE IN FINANCING AGREEMENT TO ACQUIRE UP TO 60 PERCENT OF MARQUEST MEDICAL PRODUCTS
R.P. SCHERER LISTS 6-3/4 PERCENT SENIOR NOTES ON NYSE
SCHERER ANNOUNCES A SECONDARY OFFERING AND FILES A REGISTRATION STATEMENT
R.P. SCHERER ANNOUNCES SECONDARY PUBLIC OFFERING OF ITS COMMON STOCK
Elan and Scherer Announce License for Zydis Formulation
Troy, Michigan-Based R.P. Scherer Named in Trans-Atlantic Lawsuit:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters